BioSpaceOriginal article
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil
Positive
AI Analysis
Summary
Vertex Pharmaceuticals acquired Crinetics in a deal that adds to Big Pharma's acquisition activity in the second half of 2026. The article notes that IPOs and venture capital raises are trending upward for derisked companies, while FDA decision-making continues despite leadership transitions.
Outcome Details
Crinetics acquired by Vertex Pharmaceuticals
Importance:7/10
Sentiment:
0.60
M&AacquisitionBig PharmaIPOventure capitalFDA
Read the original article
Published by BioSpace on July 8, 2026 9:45 AM